Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Large-scale cancer genome sequencing studies have revealed that chromatin regulators
are frequently mutated in cancer. In particular, more than 20% of cancers harbour mutations …

Whereas oncogenes can potentially be inhibited with small molecules, the loss of tumour
suppressors is more common and is problematic because the tumour-suppressor proteins …

Androgen receptor (AR) is a ligand-responsive transcription factor that drives terminal
differentiation of the prostatic luminal epithelia. By contrast, in tumors originating from these …

Nuclear receptor-binding SET-domain protein 1 (NSD1), a methyltransferase that catalyzes
H3K36me2, is essential for mammalian development and is frequently dysregulated in …

As epigenetic therapies continue to gain ground as potential treatment strategies for cancer
and other diseases, compounds that target histone lysine methylation and the enzyme …

Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration-resistant prostate cancers and …

Epigenetic dependencies have become evident in many cancers. On the basis of
antagonism between BAF/SWI-SNF and PRC2 in SMARCB1-deficient sarcomas, we …

Soft tissue sarcomas (STSs) are rare mesechymal malignancies characterized by distintive
molecular, histological and clinical features. Many STSs are considered as predominatly …

Brain tumors in children and adults differ greatly in patient outcomes and responses to
radiotherapy and chemotherapy. Moreover, the prevalence of recurrent mutations in …